Trending stocks today
Astrazeneca P L C (AZN-N)
NYSE:AZN
72.66
0.67
(0.93%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
This Week’s Stock Picks & BNN Top Picks Summary: ASC-N, BBAI-N and 23 Stock and 1 ETF Top Picks (Jan 31-Feb 06)3 Promising Oversold Stocks3 Best U.S. Healthcare ETFsThis summary was created by AI, based on 6 opinions in the last 12 months.
AstraZeneca PLC (AZN) is garnering positive attention from various analysts, primarily due to its strong research and development (R&D) pipeline and the promising advancement in oncology and weight loss treatments. The company is in the midst of developing a GLP-1 weight-loss solution that could revolutionize the market by eliminating the need for injections. Its current trading valuation stands at around 14x-32x earnings, with a return on equity of 16% and a projected upside potential of 30%, aiming for prices near $88. Despite facing a challenging environment, analysts believe now is a good time to invest, particularly with the company’s strong foothold in cancer drugs and rare diseases following its acquisition of Alexion. With a robust earnings outlook and the potential for significant growth in the immediate future, AstraZeneca is being recognized as a solid long-term investment.
$72.360
Unknown
The big pharma is developing a GLP-1 weight loss treatment that avoids injections -- a big game changer - and trials are looking good. The stock trades at 32x earnings and supports a 16% ROE. We recommend setting a stop-loss at $52, looking to achieve $88 -- upside potential of 30%. Yield 2.2%
(Analysts’ price target is $88.01)Very strong R&D pipeline, with new products expected. Off recent share price highs, which is a good time to buy. Margins very strong on new products. Expecting earnings to rise in the immediate future. Low double digit EPS @ 16x earnings a very strong value proposition. Will continue to hold for the long term.
Is overlooked in pharma. It boasts an amazing oncology business, including recent positive trial data on phase 2 and 3 lung cancer drugs, which could be breakthroughs. Shares have doubled in the last 5 years and has been climbing since 2016. Last April they delivered a blowout quarter with an earnings beat and a bullish forecast including a 8.5% compound annual growth rate based on doubling multi-billion drugs to 25 by 2030. Also, they are developing obesity drugs.
Less popular name within the healthcare sector. Very strong R & D pipeline - new products are expected soon. Trading at ~14x earnings which is very under valued. Excellent time to purchase shares for the long term shareholder.
They focus on cancer drugs and making massive inroads. AZN just bought Alexion, which seeks drugs for rare diseases, so the target markets are there. AZN sells at 15x PE with earnings to grow 5-10%. Dividend pays 3.5%.
(Analysts’ price target is $83.88)Highest growth rate in Pharma sector given current share price. Very attractive entry point (15x earnings). Leader in oncology channels. Chemotherapy products very strong and is a leader in R&D. Good long term hold.
The recently bought Ocosavax (a vaccine-maker) and Gracell (an early-stage Chinese biotech working on cancer treatments).
Very strong business model during the Covid-19 pandemic.
Strong line of R&D products.
Huge revision in research providing viability for top line growth.
Current share price presenting good buying opportunity.
Continues to own shares.
Astrazeneca P L C(AZN-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Astrazeneca P L C(AZN-N) Frequently Asked Questions
What is Astrazeneca P L C stock symbol?
Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N
Is Astrazeneca P L C a buy or a sell?
In the last year, 1 stock analyst published opinions about AZN-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Astrazeneca P L C.
Is Astrazeneca P L C a good investment or a top pick?
Astrazeneca P L C was recommended as a Top Pick by on . Read the latest stock experts ratings for Astrazeneca P L C.
Why is Astrazeneca P L C stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Astrazeneca P L C worth watching?
1 stock analyst on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.
What is Astrazeneca P L C stock price?
On 2025-02-10, Astrazeneca P L C (AZN-N) stock closed at a price of $72.66.
We reiterate AZN as a TOP PICK. Recently reported earnings indicated a 19% increase in earnings and revenues. Management announced positive development on 9 new drugs worth $5 billion in future revenues and a plan to invest over $800 million in Ontario creating 700 jobs. The shares trade at 18x earnings and support a 30% ROE. We recommend trailing up the stop (from $52) to $64, looking to achieve $88 -- upside potential of 21%. Yield 1.4%
(Analysts’ price target is $88.24)